Erasca, Inc. (ERAS) Financial Statements (2024 and earlier)

Company Profile

Business Address 10835 ROAD TO THE CURE, SUITE 140
SAN DIEGO, CA 92121
State of Incorp. DE
Fiscal Year End December 31
Industry (SIC) 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) (USD)

12/31/2023
Q4
9/30/2023
Q3
6/30/2023
Q2
3/31/2023
Q1
12/31/2022
Q4
9/30/2022
Q3
6/30/2022
Q2
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments, including:296,700,000317,200,000389,700,000435,600,000355,900,000371,500,000
Cash and cash equivalents112,862,000138,787,000272,756,000284,217,000219,260,000298,007,000
Short-term investments183,806,000178,458,000116,985,000151,403,000136,668,00073,469,000
Other undisclosed cash, cash equivalents, and short-term investments32,000(45,000)(41,000)(20,000)(28,000)24,000
Debt securities, available-for-sale, accrued interest, after allowance for credit loss926,000,000,0001,200,0001,000,000748,000  
Other undisclosed current assets(925,990,734,000)5,451,0007,183,0008,148,0009,851,0009,921,000
Total current assets:305,966,000323,851,000397,883,000444,496,000365,751,000381,421,000
Noncurrent Assets
Operating lease, right-of-use asset38,524,00039,168,00039,794,00040,418,00041,051,00014,778,000
Property, plant and equipment23,229,00023,908,00024,621,00024,815,00024,875,00024,191,000
Long-term investments and receivables46,891,00048,079,000  9,569,00019,313,000
Long-term investments46,891,00048,079,000  9,569,00019,313,000
Restricted cash and investments408,000408,000408,000408,000408,000408,000
Other noncurrent assets4,388,0005,248,0004,836,0004,772,0004,775,0004,712,000
Total noncurrent assets:113,440,000116,811,00069,659,00070,413,00080,678,00063,402,000
TOTAL ASSETS:419,406,000440,662,000467,542,000514,909,000446,429,000444,823,000
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities12,706,0009,588,0009,445,00033,534,00019,930,00013,239,000
Employee-related liabilities7,104,0005,161,000
Accounts payable3,701,0002,631,0003,353,00023,049,0004,319,0002,291,000
Accrued liabilities9,005,0006,957,0006,092,00010,485,0008,507,0005,787,000
Other undisclosed current liabilities14,024,00013,704,00016,078,00015,156,0007,749,0009,080,000
Total current liabilities:26,730,00023,292,00025,523,00048,690,00027,679,00022,319,000
Noncurrent Liabilities
Long-term debt and lease obligation:     53,431,00027,437,000
Liabilities, other than long-term debt53,701,00054,665,00055,567,00054,366,000  
Other liabilities761,000697,000630,000573,000  
Operating lease, liability52,940,00053,968,00054,937,00053,793,00053,431,00027,437,000
Other undisclosed noncurrent liabilities     (53,431,000)(27,437,000)
Total noncurrent liabilities:53,701,00054,665,00055,567,00054,366,00053,431,00027,437,000
Total liabilities:80,431,00077,957,00081,090,000103,056,00081,110,00049,756,000
Equity
Equity, attributable to parent338,975,000362,705,000386,452,000411,853,000365,319,000395,067,000
Common stock15,00015,00015,00015,00012,00012,000
Additional paid in capital915,847,000909,434,000901,121,000893,850,000712,407,000706,510,000
Accumulated other comprehensive income (loss)(575,000)(793,000)(514,000)(1,041,000)(1,379,000)(1,223,000)
Accumulated deficit(576,312,000)(545,951,000)(514,170,000)(480,971,000)(345,721,000)(310,232,000)
Total equity:338,975,000362,705,000386,452,000411,853,000365,319,000395,067,000
TOTAL LIABILITIES AND EQUITY:419,406,000440,662,000467,542,000514,909,000446,429,000444,823,000

Income Statement (P&L) (USD)

12/31/2023
Q4
9/30/2023
Q3
6/30/2023
Q2
3/31/2023
Q1
12/31/2022
Q4
9/30/2022
Q3
6/30/2022
Q2
Operating expenses(34,658,000)(35,970,000)(37,025,000)(138,078,000)(36,962,000)(35,905,000)
Operating loss:(34,658,000)(35,970,000)(37,025,000)(138,078,000)(36,962,000)(35,905,000)
Nonoperating income4,297,0004,189,0003,826,0002,828,0001,473,000297,000
Other nonoperating expense(49,000)(62,000)(51,000)(50,000)(49,000)(91,000)
Loss from continuing operations:(30,361,000)(31,781,000)(33,199,000)(135,250,000)(35,489,000)(35,608,000)
Loss before gain (loss) on sale of properties:(35,489,000)(35,608,000)
Net loss available to common stockholders, diluted:(30,361,000)(31,781,000)(33,199,000)(135,250,000)(35,489,000)(35,608,000)

Comprehensive Income (USD)

12/31/2023
Q4
9/30/2023
Q3
6/30/2023
Q2
3/31/2023
Q1
12/31/2022
Q4
9/30/2022
Q3
6/30/2022
Q2
Net loss:(30,361,000)(31,781,000)(33,199,000)(135,250,000)(35,489,000)(35,608,000)
Comprehensive loss:(30,361,000)(31,781,000)(33,199,000)(135,250,000)(35,489,000)(35,608,000)
Other undisclosed comprehensive income (loss), net of tax, attributable to parent218,000(279,000)527,000338,000(156,000)(272,000)
Comprehensive loss, net of tax, attributable to parent:(30,143,000)(32,060,000)(32,672,000)(134,912,000)(35,645,000)(35,880,000)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: